News | Women's Health | February 09, 2017

Breast Cancer Patients With Dense Breast Tissue More Likely to Develop Contralateral Disease

MD Anderson study finds correlation between density, cancer in other breast

dense breast tissue, contralateral breast cancer, MD Anderson study, Cancer journal

February 9, 2017 — Breast cancer patients with dense fibroglandular breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.

The study, published in the journal Cancer, is among the first to find the association between breast density (BD) and contralateral breast cancer (CBC).

According to study author Isabelle Bedrosian, M.D., a big challenge in the management of this patient population, especially as they are making surgical decisions, is trying to counsel women appropriately on their risk of developing breast cancer in the other breast.

"We know there are a number of well-established influences for developing both primary and secondary breast cancers, such as BRCA mutations, family history and the tumor's estrogen receptor status," explained Bedrosian, associate professor, breast surgical oncology. "We also know density is a risk factor for the development of primary breast cancer. However, no one has closely looked at it as a risk factor for developing contralateral disease."

The estimated 10-year risk for women with breast cancer developing CBC can be as low as 2 percent, and as high 40 percent, said Bedrosian. The dramatic range is due in large part to the variability of risk factors across the patient population, she explained.

For the retrospective, case-controlled study, the researchers identified 680 stage I, II and III breast cancer patients, all treated at MD Anderson between 1997 and 2012. BRCA patients were excluded from the study, given their known increased risk of CBC.

Women with an additional diagnosis of metachronous CBC — defined as BC in the opposite breast diagnosed more than six months after the initial diagnosis — were the "cases," and patients who had not developed CBC were the "controls." Cases and controls were matched on a 1:2 ratio based on a number of factors, including age, year of diagnosis and hormone receptor status.

"With our research, we wanted to evaluate the relationship between the mammographic breast density of the original disease and the development of metachronous breast cancer," said Carlos Barcenas, M.D., assistant professor, breast medical oncology, and the study's corresponding author.

Of the selected patients, 229 were cases and 451 were controls. The MD Anderson researchers categorized each patient's breast density by mammogram reading, assessed at the time of first diagnosis, as "nondense" or "dense," using the categorizations from the American College of Radiology.

Among the cases, 39.3 percent were classified as having nondense breast tissue and 60.7 percent as having dense breast tissue, compared to 48.3 percent and 51.7 percent, respectively, in the controls.

After adjusting for known breast cancer risk factors, the researchers found almost a two-fold increased risk of developing CBC in breast cancer survivors with dense breasts.

"Our findings have valuable implications for both newly diagnosed patients with dense breasts and for breast cancer survivors as we manage their long-term risk of a secondary diagnosis," said Barcenas. "Our future goal is to develop a risk model incorporating breast density to best assess a breast cancer survivor's risk of developing CBC."

In the long-term, the researchers hope to use this tool to counsel patients on their personal risk and their options for treatment and surveillance, if their risk is sufficiently high.

In addition to Barcenas and Bedrosian, authors on the all-MD Anderson study include: Debu Tripathy, M.D., Yu Shen, Ph.D., Banu Arun, M.D., Akshara Raghavendra, M.D., Limin Hsu, Modesto Patangan, Jr., and Arup K. Sinha, all of Breast Medical Oncology; Huong Le-Petross, M.D., and Naveen Garg, M.D., Diagnostic Radiology; and Therese Bartholomew Bevers, M.D., Clinical Cancer Prevention.

The study was supported by The University of Texas MD Anderson Cancer Center Young Breast Cancer Survivors Program.

For more information: www.canceronline.wiley.com

References

Raghavendra, A., Sinha, A.K., Le-Petross, H.T., Garg, N., et al. "Mammographic breast density is associated with the development of contralateral breast cancer," Cancer. Published online Jan. 30, 2017. DOI: 10.1002/cncr.30573

Related Content

Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...
Therapixel Appoints Matthieu Leclerc-Chalvet as CEO
News | Artificial Intelligence | July 03, 2019
Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu...
GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

Feature | Breast Imaging | July 03, 2019 | By Greg Freiherr
Productivity and its enabler — efficiency — guided the display of products at the April...
Countless possibilities can impact the future of global healthcare and AI is the first step toward breakthrough that will change the landscape of personalized medicine
Feature | Women's Health | July 03, 2019 | By Samir Parikh
Contrary to what many people believe,...

Image courtesy of GE Healthcare

Feature | Radiology Business | July 03, 2019 | By Jeffrey Hoffmeister, M.D.
Burnout in the medical profession is not uncommon, particularly as clinicians have become more overwhelmed by growing